Camurus AB Market Cap ($4.33 Billion)
Market Cap & Net Worth: Camurus AB (CAMX)
Camurus AB market cap. Camurus AB (ST:CAMX) has a market capitalization of $4.33 Billion (Skr40.20 Billion) as of November 3, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #3817 globally and #56 in its home market, demonstrating a 1.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Camurus AB's stock price Skr674.00 by its total outstanding shares 59640184 (59.64 Million). Also see how efficiently does Camurus AB generate cash for how efficiently the company converts equity into cash flow.
Camurus AB Market Cap History (2015–2026)
Camurus AB market cap history from 2015 to 2026. Data shows growth from $434.84 Million to $4.33 Billion (24.71% CAGR). Check Camurus AB stock price for real-time trading data and today's change.
Camurus AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Camurus AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Camurus AB net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.75x
Camurus AB's market cap is 1.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.37x
Camurus AB's market cap is 5.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $683.11 Million | $113.74 Million | -$80.99 Million | 6.01x | N/A |
| 2017 | $799.16 Million | $54.31 Million | -$190.57 Million | 14.72x | N/A |
| 2018 | $393.12 Million | $49.32 Million | -$234.68 Million | 7.97x | N/A |
| 2019 | $542.34 Million | $105.61 Million | -$289.87 Million | 5.14x | N/A |
| 2020 | $1.20 Billion | $336.00 Million | -$167.26 Million | 3.56x | N/A |
| 2021 | $967.87 Million | $600.57 Million | -$90.45 Million | 1.61x | N/A |
| 2022 | $1.62 Billion | $956.34 Million | $55.55 Million | 1.70x | 29.18x |
| 2023 | $3.45 Billion | $1.72 Billion | $431.44 Million | 2.01x | 8.00x |
| 2024 | $3.63 Billion | $1.87 Billion | $428.39 Million | 1.94x | 8.47x |
| 2025 | $3.95 Billion | $2.27 Billion | $735.57 Million | 1.75x | 5.37x |
Competitor Companies of CAMX by Market Capitalization
Companies near Camurus AB in the global market cap rankings as of November 3, 2026. Also see Camurus AB (CAMX) total assets for a full breakdown of the balance sheet.
Key companies related to Camurus AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Camurus AB (2015–2026)
Market capitalization of Camurus AB from 2015 to today. Between 2015 and today, Camurus AB's market cap moved from $434.84 Million to $ 4.33 Billion, with a yearly change of 24.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr4.33 Billion | +9.42% |
| 2025 | Skr3.95 Billion | +8.93% |
| 2024 | Skr3.63 Billion | +5.11% |
| 2023 | Skr3.45 Billion | +112.98% |
| 2022 | Skr1.62 Billion | +67.51% |
| 2021 | Skr967.87 Million | -19.10% |
| 2020 | Skr1.20 Billion | +120.59% |
| 2019 | Skr542.34 Million | +37.96% |
| 2018 | Skr393.12 Million | -50.81% |
| 2017 | Skr799.16 Million | +16.99% |
| 2016 | Skr683.11 Million | +57.09% |
| 2015 | Skr434.84 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Camurus AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.33 Billion USD |
| MoneyControl | $4.33 Billion USD |
| MarketWatch | $4.33 Billion USD |
| marketcap.company | $4.33 Billion USD |
| Reuters | $4.33 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more